1De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J]. J Clin Oncol, 2000, 18:2938-2947.
2Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial [J]. Lancet, 2000,355:1041-1047.
3Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor positive tumors:a new paradigm for cancer therapy [J]. Cancer, 2002,94: 1593-1611.
4Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinitecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004,350:2335-2342.
5Lievre A, bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J]. Cancer Res, 2006,66: 3992-3995.
6Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer:a cohort study [J]. Lancet Oncol, 2005,6: 279-286.
